Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Daiichi Sankyo Ltd ADR (DSNKY)

Daiichi Sankyo Ltd ADR (DSNKY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 5.73
  • Price/Book 1.14
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.8600 +4.80%
on 12/20/24
33.2100 -15.24%
on 12/03/24
-0.7500 (-2.60%)
since 11/20/24
3-Month
26.8600 +4.80%
on 12/20/24
35.1000 -19.80%
on 09/26/24
-6.4400 (-18.62%)
since 09/20/24
52-Week
26.4700 +6.35%
on 12/28/23
42.4800 -33.73%
on 08/29/24
+1.3500 (+5.04%)
since 12/20/23

Most Recent Stories

More News
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 65.35 (+1.41%)
DSNKY : 28.1500 (+1.33%)
MS : 123.44 (+2.44%)
PFE : 26.36 (+2.29%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 26.36 (+2.29%)
ABBV : 175.58 (+2.37%)
JNJ : 144.47 (+0.62%)
RHHBY : 34.5000 (+0.76%)
GMAB : 20.31 (+1.10%)
AZN : 65.35 (+1.41%)
DSNKY : 28.1500 (+1.33%)
MRK : 98.05 (-1.48%)
LLY : 767.76 (+1.35%)
NVO : 85.00 (-17.83%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 65.35 (+1.41%)
ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
DSNKY : 28.1500 (+1.33%)
GILD : 92.57 (+1.62%)
ARAY : 1.8500 (+3.35%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 65.35 (+1.41%)
ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
DSNKY : 28.1500 (+1.33%)
GILD : 92.57 (+1.62%)
ARAY : 1.8500 (+3.35%)
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

In due time, its new partnership with Daiichi Sankyo could be massive.

MRK : 98.05 (-1.48%)
DSNKY : 28.1500 (+1.33%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

PFE : 26.36 (+2.29%)
DSNKY : 28.1500 (+1.33%)
GILD : 92.57 (+1.62%)
AZN : 65.35 (+1.41%)

Business Summary

Daiichi Sankyo Co Ltd was founded on September 28, 2005. The Company is engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the...

See More

Key Turning Points

3rd Resistance Point 31.7367
2nd Resistance Point 30.5033
1st Resistance Point 29.3267
Last Price 28.1500
1st Support Level 26.9167
2nd Support Level 25.6833
3rd Support Level 24.5067

See More

52-Week High 42.4800
Fibonacci 61.8% 36.3642
Fibonacci 50% 34.4750
Fibonacci 38.2% 32.5858
Last Price 28.1500
52-Week Low 26.4700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar